Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Indonesian Telecom Tower Companies May Be Hit by Higher Interest Rates -- Market Talk

Indonesian Telecom Tower Companies May Be Hit by Higher Interest Rates -- Market Talk

Dow JonesDow Jones2026/10/13 05:56

0556 GMT - Indonesian telecom tower companies may be hit by higher interest rates, Bahana Sekuritas' Nicolas Lumy says in a research report. Dayamitra Telekomunikasi's 100% floating-rate debt profile poses a major risk in a higher rate environment, the analyst notes. Also, tower companies are locked into long-term contracts with fixed, non-negotiable lease rates, so returns will decline as their interest burden increases amid fixed revenue. The brokerage downgrades the sector's rating to neutral from overweight. However, it still likes Sarana Menara Nusantara due to its strong presence in Indonesia's Java. Bahana Sekuritas has a buy rating and a target price of 712 rupiah on Sarana Menara Nusantara's shares, which are down 0.9% at 454 rupiah. (ronnie.harui@wsj.com)

(END) Dow Jones Newswires

October 13, 2026 01:56 ET (05:56 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss